MyFinsight
Home
Blog
About
Contact
Download
Download image
something is missing
$50,000K
Receivables from
collaborative and licensing...
-$29,954K
Maturities of marketable
securities
$96,000K
Share-based compensation
$4,504K
Other prepaid and
current assets
-$1,666K
Unrecognized tax benefits
$1,474K
Amortization of right-of-use
assets
$1,056K
Other assets
-$1,025K
Depreciation and
amortization
$381K
Right-of-use lease assets
-$314K
Other
-$42K
Net cash provided by
operating activities
$73,279K
Net cash provided by
investing activities
$52,593K
Canceled cashflow
$17,137K
Canceled cashflow
$43,407K
Net increase in
cash, cash...
$120,295K
Canceled cashflow
$5,577K
Net loss
-$4,933K
Accrued
personnel-related expenses,...
-$4,867K
Deferred income taxes
-$2,999K
Operating lease
liabilities
-$2,199K
Accounts payable
-$1,468K
Amortization and accretion on
investment securities, net
$602K
Other long-term
liabilities
-$69K
Purchases of marketable
securities
$43,407K
Proceeds from option
exercises
$241K
Net cash used in
financing activities
-$5,577K
Canceled cashflow
$241K
Repurchase of shares to
satisfy tax withholding
$5,818K
Back
Back
Cash Flow
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)
source: myfinsight.com